Barclays Maintains Encompass Health(EHC.US) With Buy Rating, Maintains Target Price $113
Barclays Keeps Their Buy Rating on Encompass Health (EHC)
Encompass Health Analyst Ratings
Barclays Maintains Overweight on Encompass Health, Raises Price Target to $113
Encompass Health Analyst Ratings
Buy Rating Affirmed for Encompass Health: A Recession-Proof and Growth-Oriented Investment
Encompass Health Analyst Ratings
Encompass Health Analyst Ratings
Encompass Health (EHC) Gets a Buy From RBC Capital
RBC Lifts Price Target on Encompass Health to $95 From $83, Cites 'Strong' Q1 Results, 2024 Guidance Boost; Outperform Kept
Buy Rating Affirmed for Encompass Health on Strong Growth and Strategic Management
Encompass Health Analyst Ratings
Encompass Health Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Universal Health (UHS) and Viking Therapeutics (VKTX)
Barclays Sticks to Its Buy Rating for Encompass Health (EHC)
Encompass Health Analyst Ratings
Buy Rating Affirmed for Encompass Health Amid Regulatory Relief and Strong Fundamentals
Encompass Health Analyst Ratings
Barclays Initiates Coverage On Encompass Health With Overweight Rating, Announces Price Target of $95
Analysts Are Bullish on Top Healthcare Stocks: Encompass Health (EHC), Biogen (BIIB)